A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2009
At a glance
- Drugs Gefitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2009 Actual end date (Aug 2005) added as reported by ClinicalTrials.gov.